Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Camp4 Therapeutics (CAMP) Preferred Stock Liabilities (2023 - 2024)

Camp4 Therapeutics' Preferred Stock Liabilities history spans 2 years, with the latest figure at $162.1 million for Q3 2024.

  • On a quarterly basis, Preferred Stock Liabilities changed 0.0% to $162.1 million in Q3 2024 year-over-year; TTM through Sep 2024 was $162.1 million, a 0.0% change, with the full-year FY2023 number at $162.1 million, changed N/A from a year prior.
  • Preferred Stock Liabilities hit $162.1 million in Q3 2024 for Camp4 Therapeutics, roughly flat from $162.1 million in the prior quarter.
  • Over the last five years, Preferred Stock Liabilities for CAMP hit a ceiling of $162.1 million in Q3 2023 and a floor of $162.1 million in Q3 2023.